This journal article co-authored by CIRS, AUDA‑NEPAD, the African Medicines Agency (AMA), and University of Hertfordshire, reviews the development of the African Medicines Agency (AMA), tracing its evolution from [...]
Explore how our R&D Briefings have impacted regulatory and health technology assessment (HTA) policy worldwide. We are delighted to share with you CIRS R&D Briefing 100, a special edition [...]
How do HTA timelines and recommendations compare across Canada’s HTA agencies? At ISPOR Europe 2025, we presented a poster analysing HTA timelines and outcomes for Canada's Drug Agency (CDA‑AMC) [...]
This CIRS multi-stakeholder workshop examined strategies for embedding meaningful patient engagement and patient experience data in regulatory and HTA processes.
How quickly do oncology medicines move from EMA approval to HTA submission across Europe — and how might this change under the EU HTA Regulation? At ISPOR Europe 2025, [...]
We're pleased to share the latest CIRS newsletter with you, featuring updates from our recent workshops, global engagements, and research studies advancing medicine regulation and HTA. 🔍 What's Inside: [...]
Introduction: The implementation of Good Review Practices (GRevPs) ensures the timely, high-quality review and enhanced availability to safe, quality, and efficacious medicines. It is important, therefore, that all aspects of [...]
This CIRS multi-stakeholder workshop examined strategies for incentivising the development of medicines for common chronic diseases.
Background The World Health Organization (WHO) developed the WHO Global Benchmarking Tool (GBT) to assess and benchmark the drug regulatory systems and practices in national medicines regulatory authorities (NMRAs). [...]
“This book is a must-read for all those with interest in medicines regulation in Africa… It provides timely expert information for consideration and possible adoption during the operationalisation of [...]
